US equities |
NVDA $238.51 ▲+1.95% SPCX $167.09 ▲+5.11% MU $1,063.47 ▼-1.06% TSLA $380.35 ▲+2.63% MSFT $525.53 ▲+1.55% SNDK $1,708.83 ▼-0.65% INTC $117.24 ▼-1.75% META $742.85 ▲+2.03%
FinancialContent

Olema Pharmaceuticals, Inc. - Common Stock (NQ:OLMA)

8.205 -0.025 (-0.30%)
Delayed Quote Updated: 2:32 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Olema Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology to Participate in Upcoming Investor Conferences
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology Reports First Quarter 2025 Financial and Operating Results
From Olema Oncology
Via GlobeNewswire
News headline image
Why Sable Offshore Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Olema Oncology to Participate in Upcoming Investor Conferences
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025
From Olema Oncology
Via GlobeNewswire
News headline image
Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
From Olema Oncology
Via GlobeNewswire
News headline image
Li Auto, Xponential Fitness And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Rubrik Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology to Present at the TD Cowen 45th Annual Health Care Conference
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology Appoints Shawnte M. Mitchell, J.D. as Chief Legal Officer and Corporate Secretary
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology to Participate in Upcoming Investor Conferences
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference
From Olema Oncology
Via GlobeNewswire
News headline image
Top 3 Health Care Stocks That May Explode In Q4 ↗
 
Via Benzinga
News headline image
Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology Announces New Clinical Trial Collaboration and Supply Agreement with Novartis in Frontline Metastatic Breast Cancer as well as $250 Million Equity Private Placement
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium
Olema will host an investor conference call at 8:00 a.m. ET on December 10, 2024 
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Olema Oncology
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >